Former Leo Pharma candidate heads into big study as FDA fast-tracks assessment

Union Therapeutics is preparing a large-scale phase IIb trial to test its candidate orismilast within atopic dermatitis. On Thursday, the FDA fast-tracked the drug, potentially saving the biotech company "several months" in a potential approval case processing, the company's CFO says.
Morten Boesen, CFO at Union Therapeutics. | Photo: Union Therapeutics
Morten Boesen, CFO at Union Therapeutics. | Photo: Union Therapeutics
BY ALBERT RØNNING-ANDERSSON, TRANSLATED BY DANIEL PEDERSEN AND CATHERINE BRETT

Acquiring drug candidate orismilast from Leo Pharma in summer of last year in a deal valued up to DKK 1.2bn (USD 186.4m) has turned out to be a good decision for Union Therapeutics.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
!
!
Must contain at least 6 characters
!
Must contain at least 2 characters
!
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

!
Newsletter terms

Front page now

Further reading